Interferon-Alfa Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa  by Jarry, Anne et al.
ORIGINAL RESEARCHInterferon-Alfa Promotes Th1 Response and Epithelial Apoptosis
via Inﬂammasome Activation in Human Intestinal Mucosa
Anne Jarry,1 Florent Malard,2,3,4,5 Chantal Bou-Hanna,1 Guillaume Meurette,6
Mohamad Mohty,4,5 Jean-François Mosnier,1,7 Christian L. Laboisse,1,7 and Céline Bossard1,7
1EA4273 Biometadys, Faculté de Médecine, Université de Nantes, Nantes, France; 2Center for Research in Transplantation and
Immunology, INSERM UMR1064, Nantes, France; 3Service d’Hématologie Clinique, 6Clinique de Chirurgie Digestive et
Endocrinienne,7Service d’Anatomie et Cytologie Pathologiques, Centre Hospitalo-Universitaire de Nantes, Nantes, France;
4Centre de Recherche Saint-Antoine, INSERM UMR 938, Paris, France; 5Service d’Hématologie Clinique et de Thérapie
Cellulaire, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Paris, FranceAbbreviations used in this paper: DKK1, Dickkopf-Homolog-1; ELISA,
enzyme-linked immunosorbent assay; FLICA, ﬂuorescent-labeled
inhibitor of caspases; IFN, interferon; IL, interleukin; IL18-BP,
interleukin 18-binding protein; T-bet, T box expressed in T cells; Tc1,
cytotoxic T cells type 1; Th, T-helper; 3D, 3-dimensional; YVAD-FMK,
Tyr-Val-Ala-Asp(OMe)-ﬂuoromethylketone.
© 2016 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2016.09.007SUMMARY
Based on an ex vivo explant culture model, we decipher the
immunopathologic effects of interferon alfa on the human
intestinal mucosa. Interferon alfa causes a Th1 response
subordinated to the activation of the inﬂammasome, leading
to epithelial apoptosis involving altered epithelial Wnt/
b-catenin signaling.
BACKGOUND & AIMS: Several lines of investigation suggest that
interferon (IFN) alfa can alter human intestinal mucosa homeo-
stasis. These include the endogenous production of IFN alfa in
celiac disease or inﬂammatory bowel diseases, as well as the
occurrence of intestinal side effects of exogenous IFN alfa used as
a therapeutic tool. Here, we present an ex vivo translational
approach to investigate the effects of IFN alfa on the human
normal intestinal mucosa, as well as its underlying mechanisms.
METHODS: Human normal colonic mucosa explants were
cultured in the presence or absence of IFN alfa 2a. Epithelial
homeostasis was assessed using the immunohistochemical
marker of apoptosis M30. The Wnt inhibitor Dickkopf-Homolog-1
(DKK1) was assayed in the supernatants by enzyme-linked
immunosorbent assay. Activation of the inﬂammasome
(caspase-1/interleukin [IL]18) and of a Th1 response was
determined by in situ detection of active caspase-1, as well as by
measurement of mature IL18 production and the prototype Th1
cytokine IFN gamma by enzyme-linked immunosorbent assay. In
addition, mechanistic studies were performed using the speciﬁc
caspase-1 inhibitor Tyr-Val-Ala-Asp(OMe)-ﬂuoromethylketone
(YVAD-FMK), IL18-binding protein, neutralizing anti–IFN gamma,
and anti-DKK1 antibodies.
RESULTS: IFN alfa 2a elicited a rapid (24 hours) disruption of
surface and crypt colonic epithelial cells via apoptosis that was
variable in intensity among the 20 individuals studied. This
apoptotic effect was dependent on the initiation of an IFN
gamma response elicited by resident T box expressed in T
cells–positive lamina propria cells. Both apoptosis and Th1
response were subordinated to active caspase-1 and IL18 pro-
duction. Finally, neutralization of IFN gamma–induced DKK1
partially protected against IFN alfa–induced epithelial apoptosis.
CONCLUSIONS: By using an ex vivo model, we show an inter-
individual heterogeneity of IFN alfa effects. We show that IFNalfa is able to disrupt both epithelial and immune homeo-
stasis in the human intestine, by activation of an innate
immunity platform, the inﬂammasome, which drives a Th1
response and leads to epithelial barrier disruption. (Cell Mol
Gastroenterol Hepatol 2016;-:-–-; http://dx.doi.org/10.1016/
j.jcmgh.2016.09.007)
Keywords: Caspase-1; Mucosal Innate and Adaptive Immunity;
Roferon; DKK1.
ype I interferons (IFNs), a family composed mainlyTof IFN alfa subtypes and IFN beta, are well known as
innate cytokines produced early as the ﬁrst line of defense
against viral or bacterial infections. Type I IFNs signal via
IFN alfa receptors, which are expressed ubiquitously.1,2
Recently, it has been reported that type I IFN can have
immunomodulatory effects via direct or indirect, partially
known, mechanisms.1,3 In addition, several reports strongly
suggest that endogeneously produced IFN alfa is involved in
human intestinal immunopathologies such as celiac disease
and inﬂammatory bowel diseases.4–6 IFN alfa, represented
by IFN alfa 2a (Roferon), has been used widely in the clinic
to treat cancer and viral infections. In particular, Roferon is
used in hematologic malignancies and in solid tumors such
as melanoma, renal cell carcinoma, hepatocellular carci-
noma, as well as in viral hepatitis.7,8 The antitumor or
antiviral effects of IFN alfa most likely are owing to activa-
tion of CD4þ and CD8þ T lymphocytes and natural killer
cells by increasing their ability to kill target cells or to
produce IFN gamma, in mouse models.3,9–12 In addition, IFN
alfa increases the expression of HLA class I molecules on
cancer cell lines.13 Interestingly, IFN alfa–based therapy
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intestinal disorders (diarrhea and in rare cases pseudoin-
ﬂammatory bowel disease).14 Altogether, evidence derived
from intestinal immunopathologic observations and from
side effects elicited by IFN alfa therapy points to the human
intestinal mucosa as a target of IFN alfa by albeit still un-
known mechanisms.
The current study aimed to delineate the effects of IFN
alfa on the human normal intestinal mucosa and its
underlying mechanisms by using a translational model. To
this end, we used an ex vivo 3-dimensional (3D) model of
human normal intestinal mucosa explant culture, showing all
cell types and cellular interactions able to build innate and/
or adaptive immune responses.15,16 We investigated the
effects of IFN alfa 2a on the intestinal mucosa homeostasis,
focusing on epithelial and immune homeostasis. We show
that IFN alfa induces intestinal epithelial barrier disruption,
variable in intensity among individuals, dependent on the
initiation of a T-helper (Th)1 IFN gamma response elicited by
resident innate/adaptive immune cells of the mucosa,
involving the caspase-1/interleukin (IL)18 axis.Materials and Methods
Human Normal Colonic Mucosa Explant Culture
Macroscopically and microscopically unaffected human
normal colon was collected from 20 patients undergoing
surgery for colon cancer at the University Hospital of Nantes
(10 men and 10 women; mean age, 74 y; range, 59–88 y).Table 1.Patient Clinicopathologic Features: Experiments Perfo
Sex/age at
surgery, y
Normal colon
sample Colecto
M, 61 Right colon CRC (pT3 pN0 pM0)
M, 88 Rectosigmoid CRC (pT2 pN0 pMx)
W, 67 Right colon CRC (pT2 pN1a pM0)
W, 89 Right colon CRC (pT3 pN1b pMx)
W, 84 Left colon CRC (pT4a pN2a pMx)
W, 83 Left colon CRC (pT4b pN2b pMx)
W, 62 Left colon CRC (pT3 pN1b pMx)
W, 87 Right colon CRC (pT3 pN0 pMx)
M, 78 Left colon CRC (pTis pN0 pM0)
M, 83 Right colon CRC (pT4a pN0 pMx)
W, 45 Left colon Primary peritoneal serou
M, 86 Left colon CRC (pTis pNx pM0)
M, 70 Right colon CRC (pT1 pN0 pM0)
M, 78 Left colon CRC (pT1 pN0 pM0)
M, 82 Right colon CRC (pT3 pNx)
M, 59 Right colon CRC (pT3 pN0 pM0)
W, 76 Sigmoid CRC (pT2 pN0 pMx)
W, 58 Left colon CRC (pT3 pN0 pMx)
W, 84 Right colon CRC (pT4 pN2b pMx)
W, 73 Left colon CRC (pT1 pN0 pM0)
NOTE. pTNM stage is shown in parentheses.
CRC, colorectal cancer.Patients did not undergo radiotherapy or chemotherapy and
were not treated with immunosuppressive agents. The
patients’main clinicopathologic features are listed in Table 1.
The tissue fragments were processed according to the French
guidelines for research on human tissues. Informed patient
consent was obtained according to the French bioethics law.
Themucosawas stripped from the underlying submucosa
and pinned onto Sylgard-coated Petri dishes (VWR, Sarasota,
FL) as previously described.15 Fragments of 40 mg were
maintained in culture in RPMI/Ham F12 (1:1, vol/vol)–
bovine serum albumin 0.01%/antibiotics/fungizone for 24
hours, in the absence or presence of the indicated concen-
trations of IFN alfa 2a (PBL Assay Science, Piscataway, NJ).
The explants were maintained at 37C in a 95% O2, 5% CO2
humid atmosphere on a rocking platform at low speed. In
each experiment, 4 explants were cultured per condition.
After the 24-hour culture, the supernatants were collected,
centrifuged, and aliquots were stored at -80C for further
analysis. Some explantswere ﬁxed in formalin and embedded
in parafﬁn for histologic and immunohistochemical analyses
and some explants were frozen in liquid nitrogen and stored
at -80C for further in situ assessment of caspase-1 activation
(see later). Some experiments were performed for 24 hours in
the presence of the caspase-1 inhibitor Tyr-Val-Ala-Asp(OMe)-
ﬂuoromethylketone (YVAD-FMK) (2 mmol/L; Biovision, Clin-
isciences, Montrouge, France), the IL18 antagonist IL18-
binding protein (IL18-BP) (recombinant human IL18-BPa/
Fc protein, 800 ng/mL; Bio-Techne, Lille, France), or in
the presence of neutralizing anti–IFN gamma antibodiesrmed on Human Normal Colonic Mucosa Explant Cultures
my
Experiments performed on normal
colonic explant cultures
Control, IFN alfa (10, 100, 500 U/mL)
Control, IFN alfa (10, 100, 500 U/mL)
Control, IFN alfa (10, 100, 500 U/mL)
Control, IFN alfa (10, 100, 500 U/mL)
Control, IFN alfa (10, 100, 500 U/mL)
Control, IFN alfa 500 U/mL
Control, IFN alfa 500 U/mL
Control, IFN alfa 500 U/mL
Control, IFN alfa ± YVAD
IFN alfa ± YVAD or IL18-BP
s adenocarcinoma IFN alfa ± YVAD
Control, IFN alfa 500 U/mL ± IL18-BP
Control, IFN alfa ± YVAD or IL18-BP
Control, IFN alfa ± anti–IFN gamma
Control, IFN alfa ± IL18-BP
Control, IFN alfa ± anti–IFN gamma
IFN alfa ± anti-IFN gamma or anti-DKK1
IFN alfa ± anti-DKK1
IFN alfa ± anti-DKK1
IFN alfa ± anti-DKK1
- 2016 IFN Alfa Alters Intestinal Mucosa Homeostasis 3(2 mg/mL; Eurobio, Courtaboeuf, France) or anti-Dickkopf-
Homolog-1 (DKK1) antibodies (5 mg/mL, Biotechne).
Table 1 lists the experiments performed using the normal
colonic mucosa of each individual.
Morphology and Immunohistochemistry
Standard H&E staining was used to assess the overall
morphology and viability of the explants after a 24-hour
culture in the absence or presence of IFN alfa 2a on
parafﬁn sections. To assess epithelial apoptosis, immuno-
histochemistry was performed using the M30 cytodeath
antibody (1:200; Roche Diagnostics, Meylan, France), which
recognizes a cytokeratin-18 neoepitope that becomes
available at an early caspase cleavage event during
apoptosis and is considered a marker of apoptosis in
epithelial cells.17,18 An antibody directed to T box expressed
in T cells (T-bet) (clone 4B10, 1:200; Santa Cruz,
Clinisciences, Nanterre, France) was used to assess Th1/
cytotoxic T cells type 1 (Tc1) cells in the mucosa explant
cultures. Immunohistochemistry was performed using an-
tigen retrieval in citrate buffer with pH 6 and the BondMax
automated staining system (Leica, Nanterre, France). Dia-
minobezidine was used as a chromogen and a light nuclear
counterstaining was performed with hematoxylin. The per-
centage of M30-positive apoptotic crypts was assessed by
counting at least 100 well-oriented crypts in 3–4 explants
after 24-hour culture at magniﬁcation of 200. In normal
untreated mucosa, only a few crypts showed numerous
M30-positive apoptotic cells, usually greater than or equal
to 20% total epithelial cells. Thus, colonic crypts containing
at least 20% M30-positive cells along the crypt were
considered positive in control and IFN alfa–treated cultures.
The percentage of T-betþ cells was assessed by counting in
the lamina propria the number of T-betþ cells and the total
number of mononuclear cells in at least 5 ﬁelds at a
magniﬁcation of 200.
Cytokine Determination Assay
The following cytokines were determined by enzyme-
linked immunosorbent assay (ELISA) in the same aliquots
of culture medium, according to the manufacturers’
instructions: IFN gamma (Eurobio, Courtaboeuf, France),
IL18 and DKK1 (Bio-Techne–R&D Systems, Lille, France).
Results are expressed as picograms per milliliter.
Assay of Caspase-1 Activation In Situ
Caspase-1 activation was assessed in situ on 8-mm
unﬁxed frozen sections using the green ﬂuorescein–
ﬂuorescent-labeled inhibitor of caspases (FLICA) caspase-1 kit
(Immunohistochemistry Technologies, Bloomington, MN)
according to the manufacturer’s instructions. This assay uses
theﬂuorescent inhibitor probeﬂuorescein-YVAD-FMK to label
active caspase 1 enzyme in living cells or tissue samples.
Brieﬂy, unﬁxed frozen sections of cultured explants were
blocked with UltraV block (ThermoScientiﬁc, Waltham, MA)
for 10 minutes, incubated for 2 hours with FLICA stock solu-
tion (1:100 dilution), and washed. Nuclei then were stained
with 40,6-diamidino-2-phenylindole (1:1000; inVitrogen,Waltham,MA). Sectionsweremounted using the Prolong anti-
fade medium (InVitrogen). The ﬂuorescence was observed on
a ﬂuorescent microscope (Axiovert 200-M; Zeiss, Göttingen,
Germany) equipped with an ApoTome slider. Image process-
ing was performed using an AxioCam camera and AxioVision
software (Zeiss, Goettingen, Germany).
Statistics
The Wilcoxon matched pairs test was used to assess
differences in cytokine levels between control and treated
explant cultures or between explants treated or not with
inhibitors or neutralizing antibodies, using GraphPad Prism
(GraphPad Software, Inc, La Jolla, CA). Correlation between
IFN gamma and DKK1 levels and IFN gamma and T-betþ
cells, analyzed using Spearman rank correlation, as well as
association between IFN gamma low/high and Tbetþ low/
high subgroups, determined using the Fisher test, were
performed using SAS 9.3 software (Cary, NC). P values less
than .05 were considered signiﬁcant.
Results
IFN Alfa Alters the Human Intestinal Epithelial
Barrier Homeostasis
The ex vivo explant culture model of human normal
colonic mucosa was used to assess the effects of IFN alfa on
the overall mucosa architecture and particularly on the
epithelial barrier homeostasis. To this end, explant cultures
were incubated for 24 hours with various concentrations of
IFN alfa and then processed for standard histologic analysis
and detection by immunohistochemistry of epithelial
apoptosis using the M30 antibodies. IFN alfa induced
epithelial barrier disruption, both of the surface epithelium
and crypt base, beginning at 100 U/mL and stronger at 500
U/mL (Figure 1A, pictures). Evaluation of the percentage of
M30-positive crypts showed an apoptotic effect of IFN alfa
on epithelial cells at 100 U/mL and 500 U/mL concentra-
tions (Figure 1A). Figure 1A also shows that the apoptotic
effect of IFN alfa on the epithelial barrier was heterogeneous
among the 5 tested mucosae. The heterogeneity of the IFN
alfa–induced apoptotic effect was conﬁrmed further on
explant cultures from 14 mucosae treated with 500 U/mL
IFN alfa 2a (the 5 mucosae shown in Figure 1A and 9 other
mucosae), with a number of M30-positive apoptotic cells
ranging from 15% to 67% (Figure 1B). Of note, in 21% of
cases (3 of 14), IFN alfa did not increase epithelial barrier
apoptosis compared with control cultures.
IFN Alfa Alters the Intestinal Mucosa Immune
Homeostasis: Induction of a Th1 Response
We next examined whether IFN alfa was able to modu-
late the intestinal mucosa immune homeostasis and partic-
ularly to induce the prototype Th1 cytokine IFN gamma.
Analysis of the 24-hour explant culture supernatants by
ELISA showed that baseline levels of IFN gamma (control
cultures) were very low. IFN alfa elicited an IFN gamma
response in 4 of the 5 mucosae tested, whose levels can vary
among individuals (Figure 2A). This heterogeneity of the
Figure 1. IFN alfa alters the human intestinal barrier homeo-
stasis. (A) Intestinal mucosa explant cultures from 5 individuals
were treated or not for 24 hours with increasing concentrations
of IFN alfa 2a. The percentage of apoptotic crypts was deter-
mined after immunohistochemical staining with M30 anti-
bodies, as mentioned in the Materials and Methods section.
Representative pictures of M30 immunolabeling show that IFN
alfa induces epithelial apoptosis (brown cells), both at the
surface epithelium and crypt base, beginning at 100 U/mL and
higher at 500 U/mL. Each symbol and bar represents the mean
valueandSEMof 4 explants. (B) PercentageofM30þ apoptotic
crypts in paired control (untreated) cultures and in cultures
treated with 500 U/mL IFN alfa in mucosae from 14 individuals.
Each symbol represents the mean value of 4 explants. The
variation between the 4 explants did not exceed 15%.
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conﬁrmed further on 14 different mucosae (the 5 mucosae
shown in Figure 1A and 9 other mucosae), ranging from
20 to 560 pg/mL (Figure 2B). In 14% of cases (2 of 14), IFN
alfa did not increase the IFN gamma response compared
with control cultures. Interestingly, the IFN gamma levels
released by IFN alfa–treated explant cultures correlated
with the percentage of M30-positive apoptotic crypts
(Figure 2C).
We next assessed in situ the expression of T-bet, a
transcription factor known to direct Th1/Tc1 lineage
commitment and to control the expression of IFN gamma.19,20
T-betþ lamina propria lymphocytes, rare in control cultures,
were increased in explant cultures treatedwith 500U/mL IFN
alfa (Figure 2F). The number of lamina propria T-betþ cellswere countedonparafﬁn sections of IFN alfa–treated explants,
and correlated with the levels of IFN gamma released in the
supernatants. As shown in Figure 2D, there was a signiﬁcant
positive correlation between the percentage of lamina propria
T-betþ cells and IFN gamma levels (P ¼ .0006; Spearman
coefﬁcient, 0.7). In addition, Figure 2E shows the existence of
2 subgroups of patients, with concurrent high IFN gamma
and T-betþ cells or low IFN gamma and T-betþ cells.
We next examined whether the IFN gamma response
was associated with activation of the inﬂammasome
pathway (ie, production of mature IL18 and activation of
caspase-1). Mature IL18 was assayed by ELISA in the same
supernatant aliquots of the 14 mucosae showed in
Figure 2B (same line code). As shown in Figure 3A, IFN alfa
elicited in most individuals an increased IL18 response
compared with control cultures, variable among individuals
(range, 9–365 pg/mL). In 29% of cases (4 of 14), IFN alfa
did not increase mature IL18 release compared with control
cultures.
We next assessed the status of caspase-1, known to
mediate IL18 processing, by an in situ detection of active
caspase-1 using the FLICA assay (a ﬂuorescent-labeled in-
hibitor of caspase-1 that irreversibly binds with activated
caspase-1). In untreated control cultures, the intestinal
epithelial cells did not show caspase-1 activity, apart from
some extruded apoptotic cells at the surface epithelium; a
few mononuclear cells were FLICA positive in the lamina
propria (Figure 3B, left). Upon IFN alfa treatment, numerous
FLICA-positive epithelial cells were observed in altered,
apoptotic crypts (membrane and cytoplasmic staining)
(Figure 3B), as well as a few FLICA-positive lamina propria
mononuclear cells.The IFN Alfa–Induced Th1 Response and
Epithelial Barrier Apoptosis Are Subordinated
to the Inﬂammasome Pathway
To test whether the Th1 (IFN gamma) response and
epithelial apoptosis elicited by IFN alfa were dependent on
the caspase-1/IL18 axis, IFN alfa–treated explant cultures
were incubated or not in the presence of the speciﬁc
caspase-1 inhibitor YVAD-FMK (2 mmol/L) or in the pres-
ence of recombinant human IL18 binding protein (IL18-BP,
800 ng/mL), a speciﬁc antagonist of IL18. As shown in
Figure 4A, both YVAD and IL18-BP signiﬁcantly inhibited
the IFN gamma response elicited by IFN alfa (P ¼ .001 and
.008 vs IFN alfa alone, respectively). In addition, the number
of M30-positive apoptotic crypts induced by IFN alfa treat-
ment was inhibited signiﬁcantly by the inﬂammasome
inhibitors YVAD (P ¼ .001) and IL18-BP (P ¼ .007)
(Figure 4B, left and middle).
Finally, using the M30 apoptotic assay as an end point,
we examined the sequence of causal relationships of the
earlier-mentioned signaling events. As shown in Figure 4B
(right), blocking IFN gamma using neutralizing antibodies in
IFN alfa–treated explants led to a signiﬁcant decrease in the
number of M30þ apoptotic crypts (P ¼ .01 vs IFN alfa
alone). Knowing that the IFN gamma production elicited by
IFN alfa in mucosa explant cultures is subordinated to the
Figure 2. IFN alfa alters the human intestinal mucosa immune homeostasis and elicits a Th1 IFN gamma response. (A)
Intestinal mucosa explant cultures from 5 individuals were treated or not for 24 hours with increasing concentrations of IFN alfa
2a. IFN gamma secretion was quantiﬁed by ELISA in the culture supernatants. Each symbol and bar represents the mean value
and SEM of 4 explants. (B) IFN gamma was measured by ELISA in paired control and IFN alfa–treated mucosa explant cultures
from 14 individuals. Each symbol represents the mean value of 4 explants. The variation among the 4 explants did not exceed
20%. (C) Correlation between IFN gamma levels released in the supernatants of colonic mucosa explant cultures treated with
IFN alfa (500 U/mL, 24 hours) and the percentage of M30þ crypts. Spearman coefﬁcient, 0.9; P ¼ .0001. (D) Correlation
between IFN gamma levels and percentage of T-betþ lamina propria cells was evaluated in 24-hour explant cultures treated
with IFN alfa (500 U/mL). Spearman coefﬁcient, 0.7; P ¼ .0006. (E) Relation between IFN gamma low/high levels and T-betþ
low/high percentages was determined based on cut-off values of 30 pg/mL for IFN gamma levels and 10% for T-betþ cells.
Fisher exact test, P ¼ .0004. (F) Assessment of T-bet expression by immunohistochemistry in IFN alfa–treated explants (500 U/
mL, 24 hours). One representative case with high numbers of T-betþ lamina propria lymphocytes (brown nuclei). Nuclei are
counterstained in blue. AC, apoptotic crypts.
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Figure 3. IFN alfa activates the caspase-1/IL18 axis in the
human intestinal mucosa. (A) Measurement of mature IL18
secretion by ELISA, in the supernatants of paired control and
IFN alfa–treated intestinal mucosa explant cultures from 14
individuals. Each symbol represents the mean value of 4
explants. The variation between the 4 explants did not
exceed 20%. (B) In situ detection of active caspase-1 by the
ﬂuorescein-FLICA assay in control or IFN alfa–treated explant
cultures (500 U/mL, 24 h). In control cultures, the intestinal
epithelial cells were unstained; only rare lamina propria
mononuclear cells were observed (green). In IFN alfa–treated
explant cultures, numerous epithelial cells showed active
caspase-1 (green) in apoptotic crypts (AC), present within the
cytoplasm or at the apical membrane (arrow). Nuclei are
counterstained in blue. Representative pictures of 6 different
experiments.
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intestinal epithelial barrier via caspase-1 activation, fol-
lowed by production of IL18 and subsequent production of
IFN gamma. Two experimental controls are consistent with
our interpretation of the causal role of IL18: ﬁrst, IL18-BP
had no deleterious effect on the intestinal crypts when
used alone; second, IL18-BP had no effect on the crypt
apoptosis elicited by IFN gamma (Figure 4C).
Involvement of DKK1 in the Pro-apoptotic Effect
of IFN Alfa on the Intestinal Epithelial Barrier
IFN gamma has been reported to modulate intestinal
epithelial homeostasis via induction of the Wnt inhibitor
DKK1.21 We thus examined the following: ﬁrst, the level of
DKK1 production by ELISA, as well as the possiblecorrelation between DKK1 and IFN gamma levels, in IFN
alfa–treated explants; and, second, the effect of neutralizing
anti-DKK1 antibodies on IFN alfa–induced crypt apoptosis.
As shown in Figure 5A, variable levels of DKK1 were pro-
duced by IFN alfa–treated mucosa explant cultures. There
was a statistically signiﬁcant correlation between the
levels of DKK1 and IFN gamma produced in a given mucosa
(P ¼ .034; Spearman correlation coefﬁcient, 0.67)
(Figure 5A). Interestingly, the use of neutralizing anti-DKK1
antibodies in IFN alfa–treated explant cultures led to a
signiﬁcant decrease in the number of M30þ apoptotic
crypts (P ¼ .01 vs IFN alfa alone) (Figure 5B).Discussion
Recent reports underscore the need for deciphering the
complex interactions involving mediators and specialized
cell types that maintain human intestinal homeo-
stasis.16,22–26 The current study aimed to decipher the
mechanisms of IFN alfa action on the human adult normal
mucosa homeostasis, in ex vivo explant cultures, an inte-
grated model system maintaining the 3D architecture of the
mucosa, which allows us to highlight potential cellular
cross-talk between mucosal resident cells through diverse
cytokines.15,16 We provide here several ﬁndings showing
the following: (1) IFN alfa impairs human intestinal mucosa
homeostasis by eliciting epithelial barrier disruption via
apoptosis, (2) the IFN alfa–elicited impairment of intestinal
mucosa homeostasis is heterogenous among individuals,
and (3) the pro-apoptotic effect of IFN alfa on the intestinal
epithelial barrier is subordinated to the caspase-1/IL18/IFN
gamma axis and involves the Wnt/b-catenin pathway.
We show that IFN alfa induces a rapid (within 24 hours)
alteration of the human normal intestinal epithelial barrier
with the presence of apoptotic bodies within the crypts and
epithelial cells that shed at the surface and crypt base.
Immunostaining with M30 antibody, which recognizes a
cytokeratin-18 neo-epitope that becomes available at an
early caspase cleavage event during apoptosis,17,18
conﬁrmed that IFN alfa elicits epithelial apoptosis of the
entire crypts (no surface to base of the crypt gradient).
Noticeably, this IFN alfa–elicited apoptotic effect is variable
among individuals. In fact, some intestinal mucosae can be
considered as refractory to IFN alfa, and others as sensitive
to IFN alfa, with a variable degree of sensitivity (15%–60%
apoptotic crypts). This ex vivo ﬁnding parallels clinical ob-
servations of the interpatient variability of Roferon therapy
side effects, which can be signiﬁcant or negligible in patient
subpopulations and often dependent on the dose, route, and
schedule of administration.14 It has been reported that
approximately 60% of patients with chronic hepatitis or
cancer treated with Roferon have intestinal disorders,
especially diarrhea. Case reports also note rare cases of
pseudoinﬂammatory bowel disease subsequent to IFN alfa/
ribavirin treatment for chronic hepatitis.27,28
Next, knowing that type I IFN often can exert their
effects indirectly via the production of cytokines, we sought
to determine the potential driver of the IFN alfa–induced
intestinal barrier disruption. We focused on IFN gamma
- 2016 IFN Alfa Alters Intestinal Mucosa Homeostasis 7because IFN alfa is known to have immunomodulatory
functions and to generate a Th1 response. For example,
pegylated IFN alfa 2a treatment in patients with hepatitis C
virus infection induced a transient increase of serum IFNgamma levels.29 IFN alfa favors the production of IFN
gamma by peripheral blood mononuclear cells or natural
killer cells.30,31 Our intestinal mucosa explant culture model
is best suited to examine the cascade of events involved in
Figure 5. Involvement of the Wnt pathway in the apoptotic
effect of IFN alfa on the human intestinal barrier. (A) Intestinal
mucosa explant cultures were treated with 500 U/mL IFN alfa
for 24 hours. Levels of the Wnt inhibitor DKK1 was assessed
by ELISA in the culture supernatants of mucosae from 9
individuals and compared with the levels of IFN gamma
induced by IFN alfa (P ¼ .034; Spearman correlation coefﬁ-
cient, 0.67). Each circle represents the mean of 4 explants.
The variation between the 4 explants did not exceed 20%.
(B) Explant cultures were treated with IFN alfa (500 U/mL, 24
h) in the absence or presence of neutralizing anti-DKK1
antibodies (5 mg/mL). The number of M30þ apoptotic
crypts were counted and results were expressed as the
percentage of apoptotic crypts with IFN alfa alone (100%).
Means ± SEM of 4 experiments.
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sesses all the cell subsets and maintains the cellular
interactions required for the onset of a Th1 response.15,16
We show here that IFN alfa led to increased numbers of
T-betþ (Th1/Tc1) lamina propria T lymphocytes in IFN
alfa–sensitive mucosae, which correlated with IFN gammaFigure 4. (See previous page). The IFN alfa–induced alteratio
caspase-1/IL18 axis. Intestinal mucosa explant cultures were
or presence of the (A and B) caspase-1–speciﬁc inhibitor YVA
anti-IFN gamma antibodies (2 mg/mL) (right). (A) IFN gamma
tants. Results are expressed as the percentage of IFN gamm
(100%). (B and C) The percentage of apoptotic crypts was eva
the percentage of M30þ apoptotic crypts in IFN alfa–treated
(YVAD, anti–IL18-BP) experiments, with 4 explants per conditi
immunostainings in the various experimental conditions men
counterstained in blue). (C) Control experiment to assess that
effect on crypt apoptosis (M30þ crypts) elicited by IFN gamm
Means ± SEM of 4 explants.levels released in the explant cultures supernatants.
Noticeably, IFN gamma levels induced by IFN alfa correlated
with the percentage of M30þ apoptotic crypts in a given
mucosa. Most interestingly, we show here that the IFN
alfa–induced epithelial apoptosis is dependent on IFN
gamma production because it is inhibited signiﬁcantly by
neutralizing anti–IFN gamma antibodies. Interestingly,
although a direct effect of IFN alfa on epithelial cells cannot
be excluded, based on reductionist approaches using
porcine renal epithelial cells32 or a human intestinal colonic
cancer cell line,33 the advantage of an integrated explant
culture model is to decipher the sequence of interactions
between the various resident cell types of the human
mucosa at the tissue level.
Furthermore, we and others have shown that IFN
gamma production in the intestinal mucosa can be subor-
dinated either to IL12 or IL18 pathways.16,34,35 Preliminary
experiments in the explant culture model indicated that
very low levels of IL12 (not shown) and much higher levels
of IL18 were produced upon IFN alfa treatment, so we
focused on the caspase-1/IL18 pathway, part of the
inﬂammasome. The inﬂammasome is a multiprotein com-
plex containing the central effector protein caspase-1.36
Activation of caspase-1 leads to the maturation and secre-
tion of the proinﬂammatory cytokine IL18, a potent stimu-
lator of a Th1 response.37 It should be noted that the human
normal intestinal mucosa is a reservoir of pro–caspase-1
and pro-IL18, present in epithelial cells and in some lamina
propria macrophages, which can be activated rapidly and
can initiate a Th1 response.16 In addition, in recent reports,
using in vitro models or mouse models, including genetically
engineered mice, type I IFN has emerged as a regulator of
inﬂammasome activation, although the exact mechanism is
not understood.38–40
In this study, the intestinal mucosa explant culture
model coupled with the use of blockers of the inﬂamma-
some pathway (caspase-1 inhibitor YVAD and IL18 antag-
onist IL18-BP), shows the following events: IFN alfa
activates caspase-1 in epithelial cells and in some lamina
propria mononuclear cells, as assessed in situ by the FLICA
assay, resulting in the release of mature IL18 by these cells
and in the subsequent production of IFN gamma by lamina
propria T lymphocytes, which causes epithelial barrier
disruption. Interestingly, these effects were found to be
heterogeneous among individuals, a ﬁnding that re-
capitulates the interpatient variability of IFN alfa side effectsn of intestinal mucosa homeostasis is subordinated to the
treated with IFN alfa (500 U/mL) for 24 hours, in the absence
D-FMK (2 mmol/L) or IL18-BP (800 ng/mL) or (B) neutralizing
secretion was measured by ELISA in the culture superna-
a secreted by explant cultures treated with IFN alfa alone
luated after M30 immunolabeling. Results are expressed as
explants (100%). Means ± SEM of 3 (anti–IFN gamma) to 4
on. (B) Pictures below histograms show representative M30
tioned above the ﬁgures (apoptotic crypts in brown, nuclei
IL18-BP (800 ng/mL) has no effect when used alone and no
a (50 ng/mL) in 24-hour colonic mucosa explant cultures.
- 2016 IFN Alfa Alters Intestinal Mucosa Homeostasis 9in the clinic. This interindividual heterogeneity of response
to IFN alfa in noninﬂammatory conditions could be related
to interindividual differences in the genetic background.
Importantly, the caspase-1–IL18–IFN gamma axis recently
also was shown to be activated in Crohn’s disease cases.41 In
the context of the present study, one can speculate that a
causal relationship exists between IFN alfa production and
the activation of the inﬂammasome in Crohn’s disease.
IFN gamma is well known to modulate intestinal epithe-
lial barrier functions such as epithelial permeability via the
disassembly and/or down-regulation of tight junction pro-
teins, epithelial polarity, and secretory functions.42–45 In
addition, a recent report concluded that IFN gamma is able to
regulate the intestinal epithelial cell homeostatic functions
(ie, cell proliferation/apoptosis through the Wnt/b-catenin
pathway). Indeed, IFN gamma up-regulates the Wnt inhibitor
DKK1.21 We show a signiﬁcant correlation between IFN
gamma and DKK1 levels upon IFN alfa treatment, and of a
DKK1-dependent apoptotic effect upon IFN alfa treatment,
which allows to add the Wnt/b-catenin pathway as another
signaling pathway involved in the indirect effect of IFN alfa
on the intestinal epithelial barrier.
Altogether, this study, using a 3D model of human
normal intestinal mucosa explant culture, provides some
clues on the mechanisms involved in the intestinal immu-
nopathologic effects of IFN alfa. Indeed, this study showed
that the innate cytokine IFN alfa can activate adaptive
immune responses (ie, a Th1/Tc1 IFN gamma response), in
normal human intestinal mucosa, which is the driver of
epithelial barrier disruption, although these effects are
variable among individuals and strongly suggest that the
intestinal side effects of Roferon therapy are inherent to IFN
gamma production, which has been shown to occur rapidly
upon Roferon treatment. Interestingly, our study also
showed that IFN alfa activates the inﬂammasome, a molec-
ular platform present in numerous cell types and the IL18/
IFN gamma axis.References
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